Table 1.

Demographic, baseline clinical and therapeutic characteristics of patients

	Overall (n = 29)	Etanercept (n = 19)	Adalimumab (n = 7)	Infliximab (n = 3)	p
Gender (M/F)	40 (12/15)	13/6	1/6	0/3	NS
Age, years	37 (20–65)	46 (20–65)	34 (24–62)	35 (20–43)	NS
PASI	0.6 (0.0–5.2)	1 (0–5.2)	0.3 (0–1.2)	0.6 (0.2–2.0)	NS
HAQ	1 (0.5–2.6)	1 (0.5–2.6)	1.37 (0.5–1.6)	0.62 (0.6–1.6)	NS
Tender joints	8 (5–18)	8 (5–18)	6 (5–16)	8 (7–18)	NS
Swollen joints	3 (1–12)	3 (1–12)	3 (1–5)	2 (1–4)	NS

Values are median (range) or absolute frequency

M male, F female, NS not significant